BioSpace News Archive

Yield10 Bioscience, Inc. announced that the Company has begun its winter 2022/2023 field test and seed production program for Camelina at sites in the United States, Canada, Argentina and Chile.

Longeveron Inc. today announced the completion of enrollment in its Phase 2a trial of Lomecel-B TM in patients with mild Alzheimer’s Disease (AD).

Inozyme Pharma, Inc. today reported financial results for the third quarter ended September 30, 2022 and provided recent business highlights.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it will participate in-person at the TIDES Europe: Oligonucleotide and Peptide Therapeutics hybrid event being held on November 16-18, 2022 at the Austria Center in Vienna, Austria.

Nurix Therapeutics, Inc. presented preclinical data supporting the utility of its CBL-B inhibitors to enhance cell therapy at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, which is being held November 8 – 12th in Boston.

EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome cancer-driven immunodeficiency, today announced that new preclinical data highlighting EVOLVE™, the company’s novel costimulatory T cell engager platform, were presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Vaccinex, Inc. and its collaborators at Emory University and the Moffitt Cancer Center announced that two abstracts, including an oral presentation and a poster related to investigator-sponsored trials for pepinemab combinations, are being presented at The Society for Immunotherapy of Cancer’s 37th Annual Meeting.

Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Brain Tumor Center, is a recipient of the American Brain Tumor Association’s Discovery Grant, a one-year, $50,000 award, supporting faculty and scientists who propose high-risk, high-impact research with the potential to change current diagnostic or treatment models for brain tumor care.

Portage Biotech Inc. announced the presentation of updates from its ongoing Phase 1/2 study of PORT-2, an invariant natural killer T cell agonist for patients with non-small cell lung cancer and advanced melanoma, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting.

Vericel Corporation announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.